S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Cullinan Oncology Stock Forecast, Price & News

-1.21 (-5.17 %)
(As of 10/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume132,500 shs
Average Volume254,023 shs
Market Capitalization$967.05 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CGEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

Cullinan Oncology logo

About Cullinan Oncology

Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
($1.84) per share





Market Cap
$967.05 million
Next Earnings Date
11/9/2021 (Estimated)
Not Optionable


Overall MarketRank

2.53 out of 5 stars

Medical Sector

92nd out of 1,359 stocks

Biological Products, Except Diagnostic Industry

12th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Cullinan Oncology (NASDAQ:CGEM) Frequently Asked Questions

Is Cullinan Oncology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cullinan Oncology stock.
View analyst ratings for Cullinan Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Cullinan Oncology?

Wall Street analysts have given Cullinan Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cullinan Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,600,000 shares, an increase of 42.9% from the September 15th total of 1,820,000 shares. Based on an average daily trading volume, of 221,700 shares, the short-interest ratio is currently 11.7 days. Approximately 9.0% of the company's stock are sold short.
View Cullinan Oncology's Short Interest

When is Cullinan Oncology's next earnings date?

Cullinan Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Cullinan Oncology

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Monday, August, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02.
View Cullinan Oncology's earnings history

What price target have analysts set for CGEM?

4 equities research analysts have issued 1-year price targets for Cullinan Oncology's shares. Their forecasts range from $43.00 to $55.00. On average, they anticipate Cullinan Oncology's stock price to reach $51.75 in the next twelve months. This suggests a possible upside of 133.0% from the stock's current price.
View analysts' price targets for Cullinan Oncology
or view top-rated stocks among Wall Street analysts.

Who are Cullinan Oncology's key executives?

Cullinan Oncology's management team includes the following people:
  • Mr. Owen P. Hughes Jr., CEO, Pres & Director (Age 46, Pay $720.56k)
  • Dr. Patrick A. Baeuerle, Co-Founder & Acting Chief Scientific Officer of Biologics (Age 63, Pay $737.93k)
  • Mr. Jeffrey Trigilio, CFO & Treasurer (Age 36) (LinkedIn Profile)
  • Mr. Nate Nguyen, Director of Accounting & Controller
  • Mr. Raymond T. Keane, Chief Legal Officer & Sec. (Age 62)
  • Ms. Corinne Savill Ph.D., Acting Chief Bus. Officer (Age 62)
  • Mr. Leigh Zawel Ph.D., Chief Scientific Officer of Small Molecules (Age 55) (LinkedIn Profile)
  • Dr. Jennifer Michaelson Ph.D., Chief Devel. Officer of Biologics (Age 53) (LinkedIn Profile)
  • Ms. Kerry Whalen, Sr. Director of Preclinical & Early Devel.
  • Ms. Natasha Uzelac, Sr. Director & Head of Analytical Sciences

When did Cullinan Oncology IPO?

(CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Cullinan Oncology's stock symbol?

Cullinan Oncology trades on the NASDAQ under the ticker symbol "CGEM."

Who are Cullinan Oncology's major shareholders?

Cullinan Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Strs Ohio (0.01%). Company insiders that own Cullinan Oncology stock include Ansbert Gadicke, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel and Oncology Impact Fund LP Ubs.
View institutional ownership trends for Cullinan Oncology

Which major investors are buying Cullinan Oncology stock?

CGEM stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio.
View insider buying and selling activity for Cullinan Oncology
or or view top insider-buying stocks.

How do I buy shares of Cullinan Oncology?

Shares of CGEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cullinan Oncology's stock price today?

One share of CGEM stock can currently be purchased for approximately $22.21.

How much money does Cullinan Oncology make?

Cullinan Oncology has a market capitalization of $967.05 million. The company earns $-51.80 million in net income (profit) each year or ($5.48) on an earnings per share basis.

How many employees does Cullinan Oncology have?

Cullinan Oncology employs 24 workers across the globe.

What is Cullinan Oncology's official website?

The official website for Cullinan Oncology is www.cullinanoncology.com.

How can I contact Cullinan Oncology?

The company can be reached via phone at 617-410-4650 or via email at [email protected].

This page was last updated on 10/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.